Search
Filter Results
Displaying 491–500 of 726 for “retinal diseases”
-
Sep 25, 2020
ProQR Announces Virtual Presentations at Scientific Conferences
ResourceProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).
-
- Oct 28, 2026
- 10:00 a.m. - 12:00 p.m. (PDT)
- 9449 Campus Point Dr, La Jolla, CA 92037
Community EventExplore the Latest in Retinal Research at UC San Diego
-
- May 13, 2027
- 5:30 p.m. (EDT)
- 409 E 59th St, New York, NY 10022
Signature EventNew York Night for Sight is an unforgettable evening of dining, entertainment, and philanthropy benefiting the Foundation Fighting Blindness and its mission to find treatments and cures for blinding diseases.
-
Oct 8, 2021
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Jul 24, 2017
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
Research NewsThe Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
-
Mar 21, 2012
The Importance of Stem Cells (a guest post from Dr. David Gamm)
Research NewsDr. David Gamm on the potential of stem cell research to benefit patients with retinal degenerations.
-
Watch Mike’s powerful story and see how your donation drives research toward treatments and cures for retinitis pigmentosa and blinding diseases. Donate today.
-
Sep 12, 2025
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
Research NewsNACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
Jan 5, 2024
Eye on the Cure Podcast | Episode 59: Dr. Robert MacLaren
Eye on the CureDr. Robert MacLaren, a world-renowned retinal surgeon, clinical trial investigator, and research lab leader at the University of Oxford, talks to host Ben Shaberman about the successes and challenges in retinal gene therapy development and clinical trials, as well as advances in robotics for improving retinal surgery outcomes.
-
Apr 16, 2019
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
Research NewsThe treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10